ClinicalTrials.gg
CompletedNCT04516278Updated Jul 17, 2026Results posted

A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders

A Phase 3 interventional study of bevacizumab in Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration and Wet Macular Degeneration, sponsored by Outlook Therapeutics, Inc.. Completed at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-17.

Primary conditionWet Macular DegenerationRegistry: Macular DegenerationReclassifiedWhy we changed it
Registry
Macular Degeneration — the first condition term the registry derived for this study.
ClinicalTrials.gg
Wet Macular Degeneration
Why
  1. The study's listed conditions name Wet Macular Degeneration, a narrower term within Macular Degeneration.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Outlook Therapeutics, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
197
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 49 studies in Wet Macular Degeneration with a site in United States — 7 open to participants now, 14 under way, 7 of them phase 3. Wet Macular Degeneration · United States.

Enrollment
19th of 45
197 · median 91
Started
2020
with 5 others
Phase 3
13 of 49
1 open now
Registered
31st of 49
by date
Lead sponsor
4 of 49
Outlook Therapeutics, Inc.

Among the 49 studies in Wet Macular Degeneration with a site in United States, this one is the 19th largest by enrollment of the 45 interventional ones that give a count, is one of 6 that started in 2020, is one of 13 in phase 3, and was the 31st registered.

Wet Macular Degeneration

93 studies on the registry are indexed under Wet Macular Degeneration; 10 are open to participants now.

Browse Wet Macular Degeneration studies →

Open to participants now

7 of the 49 studies in Wet Macular Degeneration with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Wet Macular Degeneration studies recruiting now, 5 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Wet Macular Degeneration with a site in United States, or all of them as a file.
02

Study summary

The study will evaluate the safety of ophthalmic bevacizumab in subjects diagnosed with a retinal condition that would benefit from treatment with intravitreal injection of bevacizumab, including: exudative age-related macular degeneration, diabetic macular edema, or branch retinal vein occlusion.

03

Conditions studied

  • Age-related Macular Degeneration
  • Neovascular Age-related Macular Degeneration
  • Wet Macular Degeneration
  • BRVO - Branch Retinal Vein Occlusion
  • Diabetic Macular Edema

Browse trials for

04

In context

Wet Macular Degeneration Reclassified

93 studies on the registry are indexed under Wet Macular Degeneration; 10 are open to participants now.

This study's enrollment of 197 is above the median of 101 across 74 interventional studies indexed under Wet Macular Degeneration.

Browse Wet Macular Degeneration studies →

Lead sponsor

Outlook Therapeutics, Inc. is the lead sponsor of 5 studies on the registry; none are open to participants now.

Compared within Wet Macular Degeneration, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Macular Degeneration. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Active clinical diagnosis and OCT confirmation of one of the following retinal disorders: exudative age-related macular degeneration (AMD), diabetic macular edema (DME), or branch retinal vein occlusion (BRVO) and, in the opinion of the Investigator, requires treatment with an anti-VEGF therapy

Exclusion criteria

Exclusion Criteria:

  • Previous use of approved anti-VEGF or Avastin® within 4 weeks preceding randomization
  • Macular edema due to something other than exudative AMD, DME or BRVO, in the study eye
  • History of inadequate response to previous intravitreal anti-VEGF therapy
  • History of any intraocular or periocular injection or implant, in the study eye
  • Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within 1-month preceding randomization
  • Any concurrent intraocular condition in the study eye that may require medical or surgical intervention or contribute to vision loss during the study period
  • Active intraocular inflammation in the study eye
  • Current vitreous hemorrhage in the study eye
  • Polypoidal choroidal vasculopathy (PCV) in the study eye
  • History of idiopathic, infectious or -associated uveitis in either eye
  • Current ocular or periocular infection, such as conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye
  • Uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥30 mmHg despite treatment with anti-glaucoma medication)
  • Premenopausal women not using adequate
  • Current treatment for active systemic infection
  • Known allergy to any component of the study drug , not amenable to treatment
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
197 participants (actual)

Study arms

  • Experimental
    Biological: bevacizumab

    ONS-5010

    Biological: bevacizumab

Interventions

  • Biologicalbevacizumab

    1.25 mg, intravitreal injection

    Also known as: ONS-5010

07

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    Number of participants with adverse events

    Time frame: 3 months

08

Results

Posted Jul 17, 2026

Participant flow

Participant flow — Overall Study
MilestoneBiological: Bevacizumab
Started197
Completed192
Not completed5

Outcome measures

PrimaryNumber of Participants With Adverse Events

Number of participants with adverse events

Time frame:
3 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsBiological: Bevacizumab
Number of Participants With Adverse Events62

Adverse events

Collected over from enrollment until end of follow-up, up to 12 weeks. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Biological: Bevacizumab1/197 (0.5%)11/197 (5.6%)23/197 (11.7%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventBiological: Bevacizumab
AnemiaBlood and lymphatic system disorders1/197
Acute myocardial infarctionCardiac disorders1/197
Atrioventricular block completeCardiac disorders1/197
Cardiac failure acuteCardiac disorders1/197
Cardiac failure congestiveCardiac disorders1/197
Cardiogenic shockCardiac disorders1/197
Ischemic cardiomyopathyCardiac disorders1/197
Myocardial infarctionCardiac disorders1/197
Retinal hemorrhageEye disorders1/197
Chronic kidney diseaseRenal and urinary disorders1/197
Most frequent other events
Most frequent other events
EventBiological: Bevacizumab
Urinary tract infectionInfections and infestations8/197
COVID-19Infections and infestations7/197
Conjunctival haemorrhageEye disorders4/197
FallInjury, poisoning and procedural complications4/197

Baseline characteristics

Age, Customized
Age, Customized(years)Biological: Bevacizumab
Age at Screening66.2 ± 13.47
Sex: Female, Male
Sex: Female, Male(Participants)Biological: Bevacizumab
Female110
Male87
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Biological: Bevacizumab
American Indian or Alaska Native0
Asian4
Native Hawaiian or Other Pacific Islander0
Black or African American7
White175
More than one race0
Unknown or Not Reported11
09

Study locations

20 sites
  • Clinical Site
    Tucson, Arizona 85710, United States
  • Clinical Site
    Beverly Hills, California 90211, United States
  • Clinical Site
    Glendale, California 91203, United States
  • Clinical Site
    Long Beach, California 90807, United States
  • Clinical Site
    Palm Desert, California 92260, United States
  • Clinical Site
    Poway, California 92064, United States
  • Clinical Site
    Clearwater, Florida 33761, United States
  • Clinical Site
    Winter Haven, Florida 33880, United States
  • Clinical Site
    Oak Forest, Illinois 60452, United States
  • Clinical Site
    Springfield, Illinois 62704, United States
  • Clinical Site
    Hagerstown, Maryland 21740, United States
  • Clinical Site
    Albuquerque, New Mexico 87109, United States
  • Clinical Site
    Chambersburg, Pennsylvania 17201, United States
  • Clinical Site
    Rapid City, South Dakota 57701, United States
  • Clinical Site
    Germantown, Tennessee 38138, United States
  • Clinical Site
    Abilene, Texas 79606, United States
  • Clinical Site
    Arlington, Texas 76012, United States
  • Clinical Site
    McAllen, Texas 78503, United States
  • Clinical Site
    San Antonio, Texas 78251, United States
  • Clinical Site
    Willow Park, Texas 76087, United States
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Feb 2021, 4 months.

Results were first posted in Jul 2026, 5 years 5 months after primary completion. A results delay was requested in Nov 2021.

Of 16 phase 3 interventional studies under Wet Macular Degeneration, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 50. This study's 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2020
First posted
Aug 18, 2020
StartActual
Oct 1, 2020
Primary completionActual
Feb 10, 2021
CompletionActual
Feb 10, 2021
Results delay requested
Nov 16, 2021
Results first posted
Jul 17, 2026
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT04516278
Lead sponsor
Outlook Therapeutics, Inc.
Responsible party
Sponsor
First posted
Aug 18, 2020
Start date
Oct 1, 2020
Primary completion
Feb 10, 2021
Completion
Feb 10, 2021
Results posted
Jul 17, 2026
Last update
Jul 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bevacizumab

Start the discussion